Latest Share Chat

CIR.L Share News (CIR)

CIR.L Information

There is currently no data for CIR

Circassia Pharmaceuticals Notes Terminated Agreement With BeyondAir

Thu, 19th Dec 2019 09:27

(Alliance News) - Shares in Circassia Pharmaceuticals PLC dropped on Thursday after it received an agreement termination notice from BeyondAir Inc, on the grounds of material breach.

Shares in Circassia were 9.2% lower at 18.98 pence per share on Thursday morning in London.

BeyondAir is a clinical-stage medical device and biopharmaceutical company, which uses nitric oxide to treat respiratory and other diseases.

The licensing agreement concerned was for the commercial rights to the late-stage ventilator-compatible nitric oxide product LungFit PH in the US and China.

Circassia refuted the allegations "in the strongest terms" and said it would "enforce its rights under the agreement and defend its position vigorously".

By Ife Taiwo; ifetaiwo@alliancenews.com

More News

22 Jul 2014 15:14

UK Earnings, Trading Statements Calendar - Week Ahead

18 Jun 2014 09:03

Wednesday broker round-up UPDATE

Ashtead Group: Barclays ups target price from 930p to 946p retaining its overweight rating. Berkeley Group: Numis upgrades from hold to buy with a target price of 2491p. Brown (N) Group: Oriel places its buy recommendation under review. BT Group: Jefferies ups target price from 440p to 470p and k

13 Jun 2014 08:45

Circassia Pharmaceuticals Sees Positive Results From Allergy Study

LONDON (Alliance News) - Circassia Pharmaceuticals PLC said Friday it has seen positive results from a two-year follow up of a phase IIb study of a house dust mite allergy product HDM-SPIRE. Investigators reassessed patients' allergy symptoms two years after starting treatment with the prod

2 Jun 2014 09:13

Imperial Innovation Looks To Raise GBP150.0 Million In Share Placing

LONDON (Alliance News) - Imperial Innovations Group PLC Monday detailed plans to raise up to GBP150.0 million before expenses through a share placing with new and existing investors, as it looks to support its existing portfolio companies, source opportunities to invest in new technologies, and f

19 May 2014 13:11

Circassia Pharmaceuticals Funded To Progress With Allergy Treatments

LONDON (Alliance News) - Clinical-stage specialty biopharmaceutical company Circassia Pharmaceuticals PLC Monday said it is fully-funded to continue the development of its SPIRE product portfolio and bringing CAT-SPIRE to the market after raising over GBP200 million though an initial public offer

21 Mar 2014 15:31

IPO Statistics: London Main Market 2014

18 Mar 2014 17:05

DIRECTOR DEALINGS: Circassia Phamaceuticals CEO, Non-Executive Transfer Shares

LONDON (Alliance News) - Circassia Pharmaceuticals PLC Tuesday said Chief Executive Steven Harris and non-executive Director Charles Swingland transfered shares into family trusts Thursday.

Details are as follows.

18 Mar 2014 14:00

Dalata Hotel Group IPO Oversubscribed

LONDON (Alliance News) - Dalata Hotel Group PLC Tuesday said it has raised EUR265 million gross through a placing of 106 million shares under its float on AIM, with the net proceeds earmarked for the acquisition of a portfolio of 16 to 25 hotels throughout Ireland and to pay down its debt.

13 Mar 2014 10:04

Circassia Pharmaceuticals hails 'biggest ever' UK biotech IPO

Allergy treatment developer Circassia Pharmaceuticals has confirmed it is raising 200m pounds in its initial public offering, as conditional trading between brokers began on Thursday morning. The biotech firm, which was spun out of university technology transfer group Imperial Innovations, priced

Latest Share Chat

CIR.L Share News (CIR)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Circassia Pharmaceuticals Notes Terminated Agreement With BeyondAir

Login to your account

Quickpicks are a member only feature

Login to your account